scholarly journals Selection of the Optimal L-asparaginase II Against Acute Lymphoblastic Leukemia: An In Silico Approach (Preprint)

2021 ◽  
Author(s):  
Adesh Baral ◽  
Ritesh Gorkhali ◽  
Amit Basnet ◽  
Shubham Koirala ◽  
Hitesh Kumar Bhattarai
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Binding Energy ◽  
Cancer Cells ◽  
In Silico ◽  
Lymphoblastic Leukemia ◽  
Streptomyces Griseus ◽  
Homologous Proteins ◽  
E Coli ◽  
Streptomyces Collinus ◽  
Selection Of

BACKGROUND L-asparaginase II (asnB), a periplasmic protein commercially extracted from <i>E coli</i> and <i>Erwinia</i>, is often used to treat acute lymphoblastic leukemia. L-asparaginase is an enzyme that converts L-asparagine to aspartic acid and ammonia. Cancer cells are dependent on asparagine from other sources for growth, and when these cells are deprived of asparagine by the action of the enzyme, the cancer cells selectively die. OBJECTIVE Questions remain as to whether asnB from <i>E coli</i> and <i>Erwinia</i> is the best asparaginase as they have many side effects. asnBs with the lowest Michaelis constant (Km; most potent) and lowest immunogenicity are considered the most optimal enzymes. In this paper, we have attempted the development of a method to screen for optimal enzymes that are better than commercially available enzymes. METHODS In this paper, the asnB sequence of <i>E coli</i> was used to search for homologous proteins in different bacterial and archaeal phyla, and a maximum likelihood phylogenetic tree was constructed. The sequences that are most distant from <i>E coli</i> and <i>Erwinia</i> were considered the best candidates in terms of immunogenicity and were chosen for further processing. The structures of these proteins were built by homology modeling, and asparagine was docked with these proteins to calculate the binding energy. RESULTS asnBs from <i>Streptomyces griseus</i>, <i>Streptomyces venezuelae</i>, and <i>Streptomyces collinus</i> were found to have the highest binding energy (–5.3 kcal/mol, –5.2 kcal/mol, and –5.3 kcal/mol, respectively; higher than the <i>E coli</i> and <i>Erwinia</i> asnBs) and were predicted to have the lowest Kms, as we found that there is an inverse relationship between binding energy and Km. Besides predicting the most optimal asparaginase, this technique can also be used to predict the most optimal enzymes where the substrate is known and the structure of one of the homologs is solved. CONCLUSIONS We have devised an in silico method to predict the enzyme kinetics from a sequence of an enzyme along with being able to screen for optimal alternative asnBs against acute lymphoblastic leukemia.

scholarly journals Selection of the Optimal L-asparaginase II Against Acute Lymphoblastic Leukemia: An In Silico Approach

JMIRx Med ◽  
10.2196/29844 ◽  
2021 ◽  
Vol 2 (3) ◽  
pp. e29844 ◽  
Author(s):  
Adesh Baral ◽  
Ritesh Gorkhali ◽  
Amit Basnet ◽  
Shubham Koirala ◽  
Hitesh Kumar Bhattarai
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Binding Energy ◽  
Cancer Cells ◽  
In Silico ◽  
Lymphoblastic Leukemia ◽  
Streptomyces Griseus ◽  
Homologous Proteins ◽  
E Coli ◽  
Streptomyces Collinus ◽  
Selection Of

Background L-asparaginase II (asnB), a periplasmic protein commercially extracted from E coli and Erwinia, is often used to treat acute lymphoblastic leukemia. L-asparaginase is an enzyme that converts L-asparagine to aspartic acid and ammonia. Cancer cells are dependent on asparagine from other sources for growth, and when these cells are deprived of asparagine by the action of the enzyme, the cancer cells selectively die. Objective Questions remain as to whether asnB from E coli and Erwinia is the best asparaginase as they have many side effects. asnBs with the lowest Michaelis constant (Km; most potent) and lowest immunogenicity are considered the most optimal enzymes. In this paper, we have attempted the development of a method to screen for optimal enzymes that are better than commercially available enzymes. Methods In this paper, the asnB sequence of E coli was used to search for homologous proteins in different bacterial and archaeal phyla, and a maximum likelihood phylogenetic tree was constructed. The sequences that are most distant from E coli and Erwinia were considered the best candidates in terms of immunogenicity and were chosen for further processing. The structures of these proteins were built by homology modeling, and asparagine was docked with these proteins to calculate the binding energy. Results asnBs from Streptomyces griseus, Streptomyces venezuelae, and Streptomyces collinus were found to have the highest binding energy (–5.3 kcal/mol, –5.2 kcal/mol, and –5.3 kcal/mol, respectively; higher than the E coli and Erwinia asnBs) and were predicted to have the lowest Kms, as we found that there is an inverse relationship between binding energy and Km. Besides predicting the most optimal asparaginase, this technique can also be used to predict the most optimal enzymes where the substrate is known and the structure of one of the homologs is solved. Conclusions We have devised an in silico method to predict the enzyme kinetics from a sequence of an enzyme along with being able to screen for optimal alternative asnBs against acute lymphoblastic leukemia.

scholarly journals In-silico development of a method for the selection of optimal enzymes using L-asparaginase II against Acute Lymphoblastic Leukemia as an example

2020 ◽  
Author(s):  
Adesh Baral ◽  
Ritesh Gorkhali ◽  
Amit Basnet ◽  
Shubham Koirala ◽  
Hitesh K. Bhattarai
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Binding Energy ◽  
Cancer Cells ◽  
Lymphoblastic Leukemia ◽  
Streptomyces Griseus ◽  
Michaelis Constant ◽  
Homologous Proteins ◽  
E Coli ◽  
Streptomyces Collinus ◽  
Selection Of

ABSTRACTL-Asparaginase II (asnB), a periplasmic protein, commercially extracted from E. coli and Erwinia, is often used to treat Acute Lymphoblastic Leukemia. L-Asparaginase is an enzyme that converts L-asparagine to aspartic acid and ammonia. Cancer cells are dependent on asparagine from other sources for growth and when these cells are deprived of asparagine by the action of the enzyme the cancer cells selectively die. Questions remain as to whether asnB from E. coli and Erwinia is the best asparaginase as they have many side-effects. asnB with the lowest Michaelis constant (Km) (most potent), and with the lowest immunogenicity is considered the most optimal enzyme. In this paper asnB sequence of E. coli was used to search for homologous proteins in different bacterial and archaeal phyla and a maximum likelihood phylogenetic tree was constructed. The sequences that are most distant from E. coli and Erwinia were considered best candidates in terms of immunogenicity and were chosen for further processing. The structures of these proteins were built by homology modeling and asparagine was docked with these proteins to calculate the binding energy. asnBs from Streptomyces griseus, Streptomyces venezuelae and Streptomyces collinus were found to have the highest binding energy i.e. −5.3 kcal/mol, −5.2 kcal/mol, and −5.3 kcal/mol respectively (Higher than the E.coli and Erwinia asnBs) and were predicted to have the lowest Kms as we found that there is an inverse relationship between binding energy and Km. Besides predicting the most optimal asparaginase, this technique can also be used to predict the most optimal enzymes where the substrate is known and the structure of one of the homologs is solved.

scholarly journals Authors’ Response to Peer Reviews of “Selection of the Optimal L-asparaginase II Against Acute Lymphoblastic Leukemia: An In Silico Approach” (Preprint)

2021 ◽  
Author(s):  
Adesh Baral ◽  
Ritesh Gorkhali ◽  
Amit Basnet ◽  
Shubham Koirala ◽  
Hitesh Kumar Bhattarai
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Peer Review ◽  
In Silico ◽  
Lymphoblastic Leukemia ◽  
Peer Reviews ◽  
Review Reports ◽  
Selection Of

UNSTRUCTURED “These are the authors’ responses to peer review reports related to MS ID[29844].”

scholarly journals Authors’ Response to Peer Reviews of “Selection of the Optimal L-asparaginase II Against Acute Lymphoblastic Leukemia: An In Silico Approach”

JMIRx Med ◽  
10.2196/33217 ◽  
2021 ◽  
Vol 2 (3) ◽  
pp. e33217
Author(s):  
Adesh Baral ◽  
Ritesh Gorkhali ◽  
Amit Basnet ◽  
Shubham Koirala ◽  
Hitesh Kumar Bhattarai
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
In Silico ◽  
Lymphoblastic Leukemia ◽  
Peer Reviews ◽  
Selection Of

Sign in / Sign up

Export Citation Format

Share Document